{
    "clinical_study": {
        "@rank": "141464", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Compare the effects of ursodiol (ursodeoxycholic acid), with and without\n      methotrexate, on pruritus, incapacitation index, and serum markers of activity and severity\n      in patients with primary biliary cirrhosis.\n\n      II.  Compare the effects of these regimens on the development of ascites, encephalopathy,\n      varices (or bleeding from pre-existing varices), histologic liver changes, transplantation,\n      and survival.\n\n      III.  Compare the toxicity and safety of each regimen."
        }, 
        "brief_title": "Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis", 
        "condition": "Liver Cirrhosis, Biliary", 
        "condition_browse": {
            "mesh_term": [
                "Liver Cirrhosis, Biliary", 
                "Liver Cirrhosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double-blind study.  Patients are stratified by\n      participating institution and Ludwig histologic stage.\n\n      All patients are treated with ursodiol (ursodeoxycholic acid, UDCA) for 6 months.  If entry\n      criteria continue to be met, patients are randomly assigned to UDCA/methotrexate or\n      UDCA/placebo.\n\n      Combination therapy continues for at least 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- The following criteria must be met prior to study entry and\n        ursodiol treatment: Bilirubin less than 3 mg/dL Alkaline phosphatase at least 1.5 times\n        normal limits Albumin at least 3 g/dL The following criteria must be met prior to\n        randomization to Arms I and II: Primary biliary cirrhosis (PBC), i.e.: Cholestatic liver\n        disease for at least 6 months prior to randomization Liver biopsy compatible with PBC\n        within 6 months prior to randomization No biliary obstruction on ultrasound, computerized\n        tomography, or cholangiography The following exclude: Asymptomatic and stage I liver\n        histology (Ludwig classification) Hepatic encephalopathy Ascites Variceal bleeding No\n        liver disease of other etiology, e.g.: Chronic hepatitis B or C Autoimmune chronic active\n        hepatitis Alcoholic liver disease Sclerosing cholangitis Drug-induced liver disease\n        Symptomatic or obstructive gallstones --Prior/Concurrent Therapy-- At least 6 months since\n        the following immunosuppressives: Cyclosporine Tacrolimus Methotrexate At least 3 months\n        since other immunosuppressives, e.g.: Azathioprine Chlorambucil Colchicine Corticosteroids\n        Penicillamine At least 3 months since rifampin --Patient Characteristics-- Life\n        expectancy: No major illness limiting life span Hematopoietic: WBC at least 2500/mm3\n        Absolute granulocyte count at least 1500/mm3 Platelet count at least 80,000/mm3 Hepatic:\n        See Disease Characteristics Renal: Creatinine clearance at least 60 mL/min Pulmonary: No\n        diffusion capacity or vital capacity less than 50% of predicted Other: Antimitochondrial\n        antibody positive HIV antibody negative No alcoholism within the past 2 years No epilepsy\n        requiring phenytoin No malignancy within the past 5 years other than skin cancer No\n        pregnant women Adequate contraception required of fertile patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "69 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": "315", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004784", 
            "org_study_id": "199/11873", 
            "secondary_id": "UTSMC-29205400"
        }, 
        "intervention": [
            {
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "ursodiol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "Ursodeoxycholic Acid"
            ]
        }, 
        "keyword": [
            "cirrhosis", 
            "gastrointestinal disorders", 
            "primary biliary cirrhosis", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Texas", 
            "last_name": "Burton Combes", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004784"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "University of Texas", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "January 1994", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2001"
    }, 
    "geocoordinates": {}
}